
Our Approach
Our deep understanding of the key biological underpinnings of cancer and ability to identify, interrogate, and successfully drug intracellular enzyme targets enables us to advance a pipeline of unique small molecule therapeutics with expansive potential. Building upon industry-leading expertise in RNA-modifying proteins (RMPs) and our systematic mapping of both the RMP space and adjacent high-value areas for drug discovery, we’re building a flexible model that allows for a diversity of approaches to developing potentially transformative biomarker-driven cancer medicines. Our therapies are designed for both novel and known, but suboptimally-addressed, high-impact oncogenic targets with the potential to benefit large patient populations with significant unmet need.